Looking at the filing, I can identify the key facts: this is a Form 10-Q for Zai Lab Limited (NASDAQ:ZLAB) for the quarterly period ended September 30, 2026, filed November 5, 2026. The filing is a large accelerated filer, with 1,124,448,350 ordinary shares outstanding as of October 31, 2026, of which 506,386,050 were held as ADSs. The ADS symbol is ZLAB on The Nasdaq Global Market, and ordinary shares trade as 9688 on The Stock Exchange of Hong Kong Limited. The filing text provided is primarily the cover page, table of contents, and forward-looking statements section. The substantive financial data (balance sheets, income statements, MD&A figures) are referenced in the table of contents but not included in the extracted text. I will work with what is confirmed in the source.

Zai Lab Limited filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 5, 2026, covering the three and nine months ended September 30, 2026.

Key Highlights

  • Share count: As of October 31, 2026, 1,124,448,350 ordinary shares were outstanding, par value $0.000006 per share.
  • ADS holders: Of total shares outstanding, 506,386,050 ordinary shares were held in the form of American Depositary Shares, each representing 10 ordinary shares.
  • Dual listing: The company's ADSs trade under the symbol ZLAB on The Nasdaq Global Market, while ordinary shares trade under symbol 9688 on The Stock Exchange of Hong Kong Limited.
  • Filer classification: Zai Lab is classified as a large accelerated filer and is not a smaller reporting company or emerging growth company, according to the filing.
  • Reporting period: The quarterly report covers financial data for the three and nine months ended September 30, 2026, compared against the same periods in 2025.
  • Principal offices: The company disclosed principal executive offices at 899 Halei Road, Building B, Pudong, Shanghai, China 201203, and 314 Main Street, 4th Floor, Suite 100, Cambridge, MA, USA 02142.

Zai Lab's Third-Quarter 2026 Filing: Structure and Scope

Zai Lab Limited, a Cayman Islands-incorporated biopharmaceutical company, submitted its Form 10-Q for the quarterly period ended September 30, 2026, through the SEC's EDGAR system. The filing carries Commission File Number 001-38205 and covers unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2026 and 2025. The report is organized into two parts: Part I covers financial information, including balance sheets, statements of operations, comprehensive loss, shareholders' equity, and cash flows, as well as management's discussion and analysis; Part II covers legal proceedings, risk factors, and other required disclosures.

According to the filing, the company confirmed it has filed all required reports under the Securities Exchange Act of 1934 during the preceding 12 months and has submitted all required Interactive Data Files electronically. The registrant stated it is not a shell company. Zai Lab's ADS structure means each ADS listed on NASDAQ:ZLAB represents 10 ordinary shares, while the underlying ordinary shares are listed separately on The Stock Exchange of Hong Kong Limited under the symbol 9688 but are not registered or listed for trading in the United States, as the filing specifies.

The filing also includes a forward-looking statements section, which the company characterizes as subject to "inherent uncertainties, risks, and changes in circumstances." The registrant identified a range of risk factors specific to its operations, including its ability to commercialize approved products, clinical and pre-clinical development outcomes, regulatory approvals and their timing, reliance on third-party licensors and contract manufacturers, and conditions arising from its China-based operations including trade policy, government intervention, currency exchange restrictions, and legal system uncertainties. These statements are the company's own and are subject to its cautionary language as described in the filing.

What Was Disclosed

Zai Lab Limited filed its Form 10-Q for the quarter ended September 30, 2026, reporting 1,124,448,350 ordinary shares outstanding as of October 31, 2026, dual-listed on NASDAQ:ZLAB and The Stock Exchange of Hong Kong Limited under symbol 9688, and classified as a large accelerated filer.